Table 4.
Differences in participants’ characteristics between the subgroups of FCR.
| Variables | Class 1 (n = 134, 65.4%), Mean ± SD (range)/n (%) |
Class 2 (n = 72, 34.6%), Mean ± SD (range)/n (%) |
χ2/t | P |
|---|---|---|---|---|
| Age (years) | 56.84 ± 13.87 (25–86) | 59.04 ± 13.46 (22–79) | −1.1 | 0.273 |
| Gender | 0.869 | 0.351 | ||
| Male | 47 (35.07) | 30 (41.67) | ||
| Female | 87 (64.93) | 42 (58.33) | ||
| Marital status | 1.900 | 0.387 | ||
| Single | 5 (3.73) | 3 (4.17) | ||
| Married | 129 (96.27) | 68 (94.44) | ||
| Divorced | 0 | 1 (1.39) | ||
| Education | 3.077 | 0.380 | ||
| Primary school and below | 32 (23.88) | 14 (19.44) | ||
| Intermediate | 41 (30.60) | 22 (30.56) | ||
| High or vocational school | 24 (17.91) | 20 (27.78) | ||
| College and above | 37 (27.61) | 16 (22.22) | ||
| Religious belief | 0.015 | 0.904 | ||
| Yes | 8 (5.97) | 4 (5.56) | ||
| No | 126 (94.03) | 68 (94.44) | ||
| Average monthly household income (RMB) | 7.216 | 0.065 | ||
| ≤ 1000 | 16 (11.94) | 14 (19.44) | ||
| 1001–3000 | 42 (31.34) | 22 (30.56) | ||
| 3001–5000 | 25 (18.66) | 20 (27.78) | ||
| ≥ 5000 | 51 (38.06) | 16 (22.22) | ||
| Domicile | 1.194 | 0.275 | ||
| Countryside | 57 (42.54) | 25 (34.72) | ||
| Town | 77 (57.46) | 47 (65.28) | ||
| Relationship with care recipient | 3.133 | 0.372 | ||
| Spouse | 92 (68.66) | 54 (75.00) | ||
| Parents | 5 (3.73) | 0 | ||
| Offspring | 32 (23.88) | 16 (22.22) | ||
| Others | 5 (3.73) | 2 (2.78) | ||
| Employment status | 0.749 | 0.387 | ||
| Nonworking | 85 (63.43) | 50 (69.44) | ||
| On-the-job | 49 (36.57) | 22 (30.56) | ||
| Self-health status | 9.796 | 0.007 | ||
| Poor | 1 (0.74) | 3 (4.17) | ||
| General | 53 (39.55) | 41 (56.94) | ||
| Good | 80 (59.70) | 28 (38.89) | ||
| Care duration | 2.649 | 0.266 | ||
| 3–8 h/d | 18 (13.43) | 10 (13.89) | ||
| 8–13 h/d | 29 (21.64) | 9 (12.50) | ||
| > 13 h/d | 87 (64.93) | 53 (73.61) | ||
| Degree of disease understanding | 3.648 | 0.161 | ||
| Ignorant | 35 (26.12) | 14 (19.44) | ||
| Partial | 69 (51.49) | 47 (65.28) | ||
| Full | 30 (22.39) | 11 (15.28) | ||
| Comorbidities | 7.331 | 0.007 | ||
| Yes | 96 (71.64) | 38 (52.78) | ||
| No | 38 (28.36) | 34 (47.22) | ||
| Score of caregiver burden | 31.37 ± 9.43 (6–52) | 36.06 ± 10.49 (13–56) | −3.266 | 0.001 |
| Score of quality of life | 46.76 ± 5.61 (24–61) | 50.42 ± 5.20 (38–64) | −4.573 | ＜0.001 |
| Score of resilience | 23.42 ± 5.78 (12–38) | 22.39 ± 5.52 (10–39) | 1.238 | 0.217 |
| Score of anxiety | 3.88 ± 2.29 (0–14) | 5.83 ± 3.90 (1–21) | −4.527 | ＜0.001 |
| Age (patients) | 62.72 ± 13.27 (18–89) | 64.83 ± 10.86 (18–81) | −1.160 | 0.247 |
| Gender (patients) | −0.262 | 0.793 | ||
| Male | 77 (57.46) | 40 (55.56) | ||
| Female | 57 (42.54) | 32 (44.44) | ||
| Primary disease | 1.257 | 0.211 | ||
| Lymphoma | 95 (70.90) | 45 (62.50) | ||
| Multiple myeloma | 26 (19.40) | 15 (20.83) | ||
| Leukemia | 12 (8.96) | 11 (15.28) | ||
| Myelodysplastic syndrome | 1 (0.75) | 1 (1.39) | ||
| Chemotherapy protocol | −0.923 | 0.357 | ||
| R-CHOP/CHOP | 61 (45.52) | 23 (31.94) | ||
| R-CDOP/CDOP | 10 (7.46) | 9 (12.50) | ||
| VRD | 15 (11.19) | 10 (13.89) | ||
| Azacitidine/Azacitidine with venetoclax | 1 (0.75) | 5 (6.94) | ||
| IA/DA | 8 (5.97) | 3 (4.17) | ||
| Others | 39 (29.10) | 22 (30.56) | ||
| Chemotherapy frequency | −1.996 | 0.047 | ||
| 1–3 times | 77 (57.46) | 31 (43.06) | ||
| 4–6 times | 29 (21.64) | 19 (26.39) | ||
| > 6 times | 28 (20.90) | 22 (30.56) |
CDOP, cyclophosphami, liposome doxorubicin, oncovin, prednisone; CHOP, cyclophosphamide, hydroxydaunomycin, oncovin, prednisone; DA, daunorubicin, azacitidine; FCR, fear of cancer recurrence; IA, idarubicin, azacitidine; R-CDOP, rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, prednisone; R-CHOP, rituximab, cyclophosphami, liposome doxorubicin, oncovin, prednisone; SD, standard deviation; VRD, bortezomib, revlimid, dexamethasone.